Karen L Reckamp
Overview
Explore the profile of Karen L Reckamp including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
115
Citations
8260
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Sankar K, Mercer J, Jaeger E, Godden J, Williams E, Thompson M, et al.
Lung Cancer
. 2025 Feb;
201:108444.
PMID: 39961190
Purpose: DNA damage response and repair (DDR) gene alterations contribute to genomic instability and increased tumor immunogenicity, yet their clinical significance in non-small cell lung cancer (NSCLC) remains unclear. Using...
3.
Myall N, Whisenant J, Neal J, Iams W, Reckamp K, York S, et al.
JTO Clin Res Rep
. 2025 Jan;
6(2):100757.
PMID: 39866193
Introduction: Although tyrosine kinase inhibitors (TKIs) are effective against NSCLC harboring sensitizing gene mutations, acquired resistance is inevitable. Preclinical studies suggest that combining EGFR TKI and monoclonal antibody therapies may...
4.
Le J, Gasho J, Peony O, Singh A, Silos K, Kim S, et al.
Front Cardiovasc Med
. 2025 Jan;
11:1485033.
PMID: 39741660
Osimertinib is first-line treatment for epidermal growth factor (EGFR)-mutated non-small cell lung cancer (NSCLC) and has been associated with cardiotoxicity. However, the nature of cardiac remodeling and associated risk factors...
5.
Karim N, Miao J, Reckamp K, Gay C, Byers L, Zhao Y, et al.
J Thorac Oncol
. 2024 Nov;
20(3):383-394.
PMID: 39505259
Objective: To evaluate whether the addition of a poly (adenosine diphosphate-ribose) polymerase inhibitor talazoparib to maintenance immune checkpoint inhibitor atezolizumab after frontline chemoimmunotherapy improved outcomes in patients with Schlafen 11...
6.
Wang Y, Fernandez A, Pei X, Liu B, Shen L, Yan Y, et al.
Nucleic Acids Res
. 2024 Oct;
52(21):13057-13072.
PMID: 39470734
Efficient DNA replication requires highly coordinated programs for the timely recruitment of protein complexes to DNA replication forks. Defects in this process result in replication stress, which in turn activates...
7.
Liu L, Soler J, Reckamp K, Sankar K
Int J Mol Sci
. 2024 Sep;
25(18).
PMID: 39337530
Lung cancer is responsible for a high burden of disease globally. Over the last two decades, the discovery of targetable oncogenic genomic alterations has revolutionized the treatment landscape for early-stage...
8.
Figueiredo J, Levy J, Choi S, Xu A, Merin N, Hamid O, et al.
iScience
. 2024 Sep;
27(9):110596.
PMID: 39286512
Patients with cancer are at increased risk of death from COVID-19 and have reduced immune responses to SARS-CoV2 vaccines, necessitating regular boosters. We performed comprehensive chart reviews, surveys of patients...
9.
Somisetty M, Mack P, Hsu C, Huang Y, Gomez J, Rodilla A, et al.
Clin Lung Cancer
. 2024 Aug;
25(7):612-618.
PMID: 39122606
Introduction: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may be spread by individuals unaware they are infected. Such dissemination has heightened ramifications in cancer patients, who may need to visit...
10.
Gettinger S, Song Z, Reckamp K, Moscow J, Gray R, Wang V, et al.
JCO Precis Oncol
. 2024 Jul;
8:e2300725.
PMID: 38986051
Purpose: National Cancer Institute-Molecular Analysis for Therapy Choice (NCI-MATCH) was a multicohort phase 2 trial that assigned patients with advanced pretreated cancers to molecularly targeted therapies on the basis of...